Synvista Therapeutics, Inc. (SYNI)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
170 - Avg. Volume
352 - Market Cap (intraday)
2 - Beta (5Y Monthly) 35.21
- PE Ratio (TTM)
-- - EPS (TTM)
-7.6570 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company's products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease. The company, formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Montvale, New Jersey.
9
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: SYNI
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYNI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYNI
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.59%
Return on Equity (ttm)
-102.91%
Revenue (ttm)
54.73k
Net Income Avi to Common (ttm)
-19.8M
Diluted EPS (ttm)
-7.6570
Balance Sheet and Cash Flow
Total Cash (mrq)
7.96M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.78M
Research Analysis: SYNI
Company Insights: SYNI
SYNI does not have Company Insights